Physician profile
Kyle D Elmore
NPI 1235194895
$5,612.72
in general payments reported to CMS, 2019-2025
38 companies · $1,435 in 2025
The $1,435 reported for 2025 was more than what 91% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $641 · 2020: $242 · 2021: $452 · 2022: $517 · 2023: $970 · 2024: $1,356 · 2025: $1,435.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,761.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,760.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $945.69 | 2019-2025 | |
| Lilly USA, LLC | $803.94 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Abbvie INC. | $651.81 | 2022-2025 | |
| Amgen INC. | $598.51 | 2019-2025 | Evenity, Prolia, Repatha |
| Novo Nordisk INC | $570.60 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $402.87 | 2020-2025 | Breztri, Farxiga, Airsupra |
| Astellas Pharma US INC | $329.58 | 2019-2025 | Veozah |
| Amarin Pharma, INC. | $149.64 | 2021-2022 | |
| Glaxosmithkline, LLC. | $133.39 | 2021-2025 | Penmenvy, Shingrix, Arexvy |
| Novartis Pharmaceuticals Corporation | $132.20 | 2019-2025 | |
| Phathom Pharmaceuticals, INC. | $87.13 | 2024-2025 | Voquezna |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $82.47 | 2025 | Caplyta |
| Sanofi-Aventis U.S. LLC | $58.68 | 2019-2024 | |
| Idorsia Pharmaceuticals US INC | $54.69 | 2023 | Quviviq |
| Radius Health, INC. | $45.34 | 2025 | Tymlos |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kyle Elmore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.